title: Longitudinal tracking of FTLD: toward developing clinical trial methodology.
abstract: Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.
authors: Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. knopman@mayo.edu
authors: David S
authors: DS
authors: Knopman
authors: Bradley S
authors: BS
authors: Boeve
authors: Richard J
authors: RJ
authors: Caselli
authors: Neill R
authors: NR
authors: Graff-Radford
authors: Joel H
authors: JH
authors: Kramer
authors: Mario F
authors: MF
authors: Mendez
authors: Bruce L
authors: BL
authors: Miller
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D002986:Clinical Trials as Topic / Q000379:methods*; D003704:Dementia / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D012107:Research Design
chemical_list: D015415:Biomarkers